Trial Bank
10 trials match
- ORION: A Study to Describe Multiple Sclerosis Patients Treated With Tolebrutinib as Per Label in a Real-world Setting
MSMS (type not specified)Recruiting
tolebrutinib · Sanofi · 2026 · 3,000 participants
- LTS17043: A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis
MSRelapsing and progressivePhase 3Running, not recruiting
tolebrutinib · Sanofi-Aventis Recherche & Developpement · 2024 · 1,405 participants
- A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
MSRelapsing and progressivePhase 3Running, not recruiting
tolebrutinib · Sanofi · 2024 · 2,500 participants
- MSBenefiT: A Randomized Open Label Trial Exploring the Soluble and Imaging Biomarker Dynamic Responses to Tolebrutinib Compared to Rituximab Treatment in Patients with Multiple Sclerosis (MS)
MSMS (type not specified)Phase 3Not yet recruiting
tolebrutinib · Region Stockholm – SLSO · 2026 · 60 participants
- PERSEUS: Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
MSProgressive MSPhase 3Completed
tolebrutinib · Sanofi · 2020 · 767 participants
- Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis
MSRelapsing MSPhase 2Completed
tolebrutinib · Sanofi · 2019 · 125 participants
- GEMINI 1: Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)
MSRelapsing MSPhase 3Completed
tolebrutinib · Sanofi · 2020 · 974 participants
- GEMINI 2: Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)
MSRelapsing MSPhase 3Completed
tolebrutinib · Sanofi · 2020 · 899 participants
- HERCULES: Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)
MSProgressive MSPhase 3Completed
tolebrutinib · Sanofi · 2020 · 1,131 participants
- Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis
MSMS (type not specified)Phase 2Status unknown
tolebrutinib · National Institute of Neurological Disorders and Stroke (NINDS) · 2021 · 12 participants
About this data
Where the data comes from
ClinicalTrials.gov, the EU Clinical Trials Register, ISRCTN, ChEMBL and Europe PMC, combined into the MSFrontier trial bank.
How it is collected
Registry records are collected automatically, duplicate records across registries are merged, and treatments, phases and populations are tagged by software from the registry data. When an error is reported, we fix the rule so the fix applies to every trial, and log it in the Corrections log.
Last update
Trial bank updated recently. Sources and corrections
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error